Trial Profile

An open-label, observational study characterizing proteomic, radiomic, clinical, behavioral, and functional trajectories of patients stable on natalizumab, ocrelizumab, and diroximel fumarate

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diroximel-fumarate (Primary) ; Natalizumab (Primary) ; Ocrelizumab (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use

08 Apr 2024 New trial record
02 Mar 2024 An interim analysis will be performed when half of the participants (n=77, with no less than 15 participants in any individual treatment group) have completed the Month 6 visit as per study design presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
02 Mar 2024 Trial design presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com